ClpP agonists induce degradation of mitochondrial proteins (e.g., TFAM, mitochondrial elongation factor Tu [TUFM], and ETC complex proteins), depletion of mtDNA copy number, downregulation of OxPhos, loss of ATP, mitochondrial structural damage, and elevation of ROS level in multiple breast cancer cell lines [58,269,270,304]. Here, CLPP is linked to breast carcinoma.